Meet Our Team
Contact our expert team to experience the only non-Invasive Vagus Nerve Stimulation device approved under the European Medical Device Regulation.
With its non-invasive approach, patient-friendly treatments, and minimal side effects, tVNS® offers a new horizon of hope and relief for those living with neurological conditions. Embrace a future where each day holds the promise of greater comfort and enhanced quality of life.
Certified Medical Device
tVNS® is the world’s only non-invasive vagus nerve stimulation approved as a Class IIa medical device under the EU-MDR, offering a scientifically validated treatment for conditions related to sympathovagal imbalance.
Non-Invasive Approach
A safe and gentle alternative to surgery and medication, tVNS® stimulates the vagus nerve through the skin, offering a harmonious path to wellbeing with very low side-effects.
Control at Your Fingertips
Use our innovative tVNS® device anywhere and monitor your treatment through our user-friendly app. You have the freedom to tailor your therapy to your lifestyle.
Most Effective Stimulation Site
tVNS® is the only non-invasive stimulation device that stimulates the cymba concha, resulting in 100% vagus nerve innervation (as opposed to e.g. the tragus, which only results in 45% innervation).
The tVNS® E is currently the only transcutaneous vagus nerve stimulation device approved in Europe according to the new Medical Device Regulation (MDR EU 2017/745). The tVNS® E is explicitly approved for the following indications:
Currently the only transcutaneous, non-invasive vagus nerve stimulation device approved in Europe under the new Medical Device Regulation (MDR EU 2017/745).
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
Currently the only transcutaneous, non-invasive vagus nerve stimulation device approved in Europe under the new Medical Device Regulation (MDR EU 2017/745).
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
Currently the only transcutaneous, non-invasive vagus nerve stimulation device approved in Europe under the new Medical Device Regulation (MDR EU 2017/745).
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
Currently the only transcutaneous, non-invasive vagus nerve stimulation device approved in Europe under the new Medical Device Regulation (MDR EU 2017/745).
After a 20 week treatment period, active tVNS® patients recorded an average 34.2% reduction of seizure frequency.
tVNS® has already been featured in numerous renowned national and international health science, and innovation media outlets for it’s evidence-based approach to non-invasive vagus nerve stimulation. The coverage underlines the growing medical-stimulation interest in transcutaneous vagus nerve stimulation and the importance of clinically sound technology certified according to the European Medical Device Regulation (MDR).
Click the publications logo that you would like to see, or scroll below and click on the article you would like to read.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Worldwide, more and more patients, researchers and doctors are having positive experiences with tVNS. These insights help us to continuously improve tVNS therapy and use it in a targeted manner.
“Epilepsy had me always bracing for the next episode. Since integrating tVNS®, there’s been a marked change in the regularity of my seizures. It’s more than relief; it’s empowerment.”
“The weight of depression had become an all-too-familiar companion. While the journey continues, tVNS® has offered a supportive hand, complementing my therapies and blessing me with brighter days.”
“It’s wonderful that with tVNS® I have found a treatment option for my Epilepsy that makes me feel better without needing surgery and worrying about side-effects.”
“Epilepsy had me always bracing for the next episode. Since integrating tVNS®, there’s been a marked change in the regularity of my seizures. It’s more than relief; it’s empowerment.”
“Epilepsy had me always bracing for the next episode. Since integrating tVNS®, there’s been a marked change in the regularity of my seizures. It’s more than relief; it’s empowerment.”
Navigating treatment options can be overwhelming, especially when conventional therapies fall short. tVNS® offers a non-invasive approach by gently stimulating the vagus nerve through the ear, supporting balance within the nervous system without surgery or medication-related side effects. Approved as a Class IIa medical device under the EU-MDR, it combines safety, simplicity, and scientific rigor.
With over 20 years of experience, we are pioneers in non-invasive vagus nerve stimulation. Backed by robust clinical research and developed and manufactured in Germany, our devices are trusted worldwide by clinicians and researchers for their precision, reliability, and high quality standards.
What Makes Our Device Special?
Our tVNS® device is the only non-invasive VNS device that is approved as a medical device under the EU-MDR.
of experience pioneering the non-invasive vagus nerve stimulation,
of the vagus nerve is achieved via stimulation of the cymba concha.
of experience pioneering the non-invasive vagus nerve stimulation.
Transcutaneous aricular vagus nerve stimulation with the tVNS® E is a systemic therapy. Here, sensory fibers of the vagus nerve in the Cymba Conchae of the auricle (outer ear) are addressed, which send the signal further to the brainstem and the cerebral cortex. From there, the signal travels back into the body’s trunk to almost all organs.
Stimulation of the afferent branches of the vagus nerve in the ear can therefore influence all major organ systems and thus many different diseases and pathophysiologies. Numerous research projects are currently underway worldwide for conditions such as stroke, ME/CFS, Sleep Disorders, Parkinson’s, Chronic Inflammatory Bowel Diseases or Atrial Fibrillation.
In this unboxing video, we walk you through the tVNS® device step by step, showing exactly what’s included and how to get started. You’ll see how to set up the device, place the electrode correctly, and begin your first session with confidence. Designed to be intuitive and easy to use at home, this guide helps ensure a smooth start and supports safe, comfortable integration of tVNS® into your daily routine.
